JOURNAL ARTICLE

Immune checkpoint inhibitors: A potential bright spot in the treatment of progressive multifocal leukoencephalopathy in multiple sclerosis.

  • Published In: Multiple Sclerosis Journal, 2023, v. 29, n. 2. P. 306 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Motte, Jeremias; Gold, Ralf 3 of 3

Abstract

Keywords: Multiple sclerosis; fingolimod; progressive multifocal leukoencephalopathy; pembrolizumab; comment EN Multiple sclerosis fingolimod progressive multifocal leukoencephalopathy pembrolizumab comment 306 307 2 02/14/23 20230201 NES 230201 Treatment of multiple sclerosis (MS) is currently facing the challenge of early use of highly effective immunotherapies to prevent subsequent progression, yet at a desired minimal risk of severe side effects. In this issue, Barritt et al. present a case report of a successful treatment of fingolimod-associated PML with pembrolizumab in a patient with relapsing-remitting MS. With persistent JC virus load in CSF, restart of the immunotherapy for MS implies the risk of deterioration of PML. [Extracted from the article]

Additional Information

  • Source:Multiple Sclerosis Journal. 2023/02, Vol. 29, Issue 2, p306
  • Document Type:Article
  • Subject Area:Consumer Health
  • Publication Date:2023
  • ISSN:1352-4585
  • DOI:10.1177/13524585221137275
  • Accession Number:161823995
  • Copyright Statement:Copyright of Multiple Sclerosis Journal is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.